| abstract |
The present invention relates to a pharmaceutical composition comprising N- [1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl) -2,2-dimethylpropanamide as an active ingredient, or a pharmaceutically acceptable salt thereof, in combination with an HMG-CoA reductase inhibitor. For the pharmaceutical compositions according to the invention, preferably the pharmaceutically acceptable salt of N- [1-ocole-5-carboxymethyl-4,6-dimethylindolin-7-yl) -2,2-dimethylpropanamide, such as the sulfate salt, and pravastatin, lovastatin, simvastatin, as HMG-CoAreductase inhibitor. fluvastatin, rivastatin, atorvastatin, rosuvastatin or quartastastatin are used. The invention also relates to pharmaceutical kits comprising the above components, wherein the active ingredients are contained in a separate carrier. The invention also relates to the use of N- [1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl) -2,2-dimethylpropanamide or a pharmaceutically acceptable salt thereof in combination with an HMG-CoA reductase inhibitor for the treatment or prevention of atherosclerosis or xanthoma. for the preparation of a preparation. The components of the pharmaceutical compositions may be administered simultaneously, separately or sequentially. SHE |